Meeder Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Meeder Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.66K	Buy	+30	New	+$2.19K	﹤0.01%	906
2026 Q1	–	Sell	-181	Closed	-$5.93K	–	1010
2025 Q4	$5.93K	Sell	181 -35	-16%	-$915	﹤0.01%	772
2025 Q3	$3.62K	Buy	216 +46	+27%	+$750	﹤0.01%	719
2025 Q2	$2.54K	Buy	+170	New	+$2.52K	﹤0.01%	799
2020 Q2	–	Sell	-9	Closed	-$1K	–	2450
2020 Q1	$1K	Sell	9 -39	-81%	-$6.63K	﹤0.01%	2232
2019 Q4	$10K	Buy	48 +41	+586%	+$8.05K	﹤0.01%	1568
2019 Q3	$1K	Sell	7 -6	-46%	-$1.17K	﹤0.01%	2085
2019 Q2	$2K	Sell	13 -270	-95%	-$46.7K	﹤0.01%	1880
2019 Q1	$57K	Buy	283 +78	+38%	+$16.3K	﹤0.01%	843
2018 Q4	$38K	Buy	205 +64	+45%	+$13.6K	﹤0.01%	888
2018 Q3	$35K	Buy	+141	New	+$32.9K	﹤0.01%	886

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Meeder Asset Management's SYRE Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 30 shares worth $2.66K. The stake represents ﹤0.01% of the portfolio and ranks #906 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in SYRE as recently as Q4 2025.

Meeder Asset Management first reported a position in SYRE in Q3 2018 and has held it in 11 quarters since. The position peaked at $57K in Q1 2019. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Meeder Asset Management held 30 shares of Spyre Therapeutics worth $2.66K as of Q2 2026.
Spyre Therapeutics was a new Meeder Asset Management position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #906 holding.
Meeder Asset Management first reported a position in Spyre Therapeutics in Q3 2018 and has held it in 11 quarters since.
Meeder Asset Management's Spyre Therapeutics position peaked at $57K in Q1 2019.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.